Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | -1.31% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | -1.31% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about their future projects. They are focused on maintaining momentum in their clinical development.
Management highlighted ongoing progress in their clinical trials.
They emphasized their commitment to advancing their pipeline despite current challenges.
Kodiak Sciences reported a loss per share that was slightly worse than expected, but the stock rose by 2.56% following the earnings announcement. Investors may be reacting positively to management's comments about progress in clinical trials, indicating potential future growth. The lack of revenue data and guidance suggests uncertainty about immediate financial performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EXELON CORP
May 8, 2020